tetano
Editor, Senior Moderator
Nanomedicine. 2016 Sep 1. pii: S1549-9634(16)30147-2. doi: 10.1016/j.nano.2016.08.030. [Epub ahead of print]
[h=1]Vaccination with Self-Adjuvanted Protein Nanoparticles Provides Protection against Lethal Influenza Challenge.[/h] Karch CP[SUP]1[/SUP], Li J[SUP]2[/SUP], Kulangara C[SUP]3[/SUP], Paulillo SM[SUP]3[/SUP], Raman SK[SUP]3[/SUP], Emadi S[SUP]4[/SUP], Tan A[SUP]4[/SUP], Helal ZH[SUP]5[/SUP], Fan Q[SUP]6[/SUP], Khan MI[SUP]7[/SUP], Burkhard P[SUP]8[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Current influenza vaccines should be improved by the addition of universal influenza vaccine antigens in order protect against multiple virus strains. We used our self-assembling protein nanoparticles (SAPNs) to display the two conserved influenza antigens M2e and Helix C in their native oligomerization states. To further improve the immunogenicity of the SAPNs we designed and incorporated the TLR5 agonist flagellin into the SAPNs to generate self-adjuvanted SAPNs. We demonstrate that addition of flagellin does not affect the ability of SAPNs to self-assemble and that they are able to stimulate TLR5 in a dose dependent manner. Chickens vaccinated with the self-adjuvanted-SAPNs induce significantly higher levels of antibodies than unadjuvanted-SAPNs and show higher cross-neutralizing activity compared to a commercial inactivated virus vaccine. Upon immunization with self-adjuvanted-SAPNs mice were completely protected against a lethal challenge. Thus, we have generated a self-adjuvanted-SAPN with a great potential as a universal influenza vaccine.
Copyright ? 2016. Published by Elsevier Inc.
[h=4]KEYWORDS:[/h] Flagellin; Influenza; M2e; Nanoparticle; Vaccine
PMID: 27593488 DOI: 10.1016/j.nano.2016.08.030
[PubMed - as supplied by publisher]
[h=1]Vaccination with Self-Adjuvanted Protein Nanoparticles Provides Protection against Lethal Influenza Challenge.[/h] Karch CP[SUP]1[/SUP], Li J[SUP]2[/SUP], Kulangara C[SUP]3[/SUP], Paulillo SM[SUP]3[/SUP], Raman SK[SUP]3[/SUP], Emadi S[SUP]4[/SUP], Tan A[SUP]4[/SUP], Helal ZH[SUP]5[/SUP], Fan Q[SUP]6[/SUP], Khan MI[SUP]7[/SUP], Burkhard P[SUP]8[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Current influenza vaccines should be improved by the addition of universal influenza vaccine antigens in order protect against multiple virus strains. We used our self-assembling protein nanoparticles (SAPNs) to display the two conserved influenza antigens M2e and Helix C in their native oligomerization states. To further improve the immunogenicity of the SAPNs we designed and incorporated the TLR5 agonist flagellin into the SAPNs to generate self-adjuvanted SAPNs. We demonstrate that addition of flagellin does not affect the ability of SAPNs to self-assemble and that they are able to stimulate TLR5 in a dose dependent manner. Chickens vaccinated with the self-adjuvanted-SAPNs induce significantly higher levels of antibodies than unadjuvanted-SAPNs and show higher cross-neutralizing activity compared to a commercial inactivated virus vaccine. Upon immunization with self-adjuvanted-SAPNs mice were completely protected against a lethal challenge. Thus, we have generated a self-adjuvanted-SAPN with a great potential as a universal influenza vaccine.
Copyright ? 2016. Published by Elsevier Inc.
[h=4]KEYWORDS:[/h] Flagellin; Influenza; M2e; Nanoparticle; Vaccine
PMID: 27593488 DOI: 10.1016/j.nano.2016.08.030
[PubMed - as supplied by publisher]